BofA analyst Jason Zemansky raised the firm’s price target on Keros Therapeutics (KROS) to $19 from $18 and keeps a Neutral rating on the shares after adjusting projections following the company’s Q3 earnings update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
- Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
- Keros Therapeutics Reports Strong Revenue Growth
- Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
- Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating